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Despite so many global efforts, smoking still remains to be one of the most common addictions worldwide. 
Even though most smokers wish to quit smoking, many of them fail. In this respect, genetic variants 
are thought to be remarkable factors in nicotine dependence and in treatment of smoking cessation. 
This is a paper investigating a single variant p-glycoprotein (P-gp) polymorphisms and its effect on 
Varenicline efficacy in the smoking cessation. 158 smokers and 52 non-smoker healthy volunteers were 
included. We determined the P-gp C3435T gene polymorphisms in all subjects. Face to face interviews 
with smokers were performed for smoking cessation and Varenicline was given for smoking cessation. 
Cessation success was evaluated in the 6th month and success rates were compared according to the 
P-gp genotype distributions. In our study, smoking cessation rate by Varenicline was 57.0%. This rate 
was 55.0% in females, and 57.2% in males (p=0.85). The P-gp C3435T gene distribution was similar 
in control, quitters and not-quitter groups. Cessation rate was at highest point in genotype CT (62.2%) 
and at the lowest in TT (47.6%). It was 53.8% in genotype CC and there was no statistically significant 
difference (p=0.27). Our results suggest that genetic variants of P-gp C3435T did not significantly affect 
Varenicline treatment for smoking cessation.
Keywords: Polymorphism. Smoking Cessation/methods. Varenicline/analysis. Varenicline/adverse 
effects. Smoking/genetics. Genetic/drug effects.
INTRODUCTION
Smoking is common in all countries and a major 
cause of mortality and health problems in worldwide (Jha, 
Peto, 2014). According to the World Health Organization 
(2012), globally 12% of all deaths among adults aged 30 
years and over were attributed to tobacco. 
Several studies have reported that 60–70% of 
smokers wish to quit (Aveyard, West, 2007), but only 
3–5% of them remain abstinent for a year after an 
unassisted attempt (Zhu et al., 2000). 
In this respect, pharmacological treatment remains an 
important resource for smoking cessation. Generally, three 
pharmaceutical interventions are Nicotine Replacement 
Therapy, Varenicline and Bupropion (Mills et al., 2012). 
Varenicline is a partial agonist at the α4β2 nicotinic 
acetylcholine receptor (Rollema et al., 2010; Obach et al., 
2006). Previous studies have indicated that Varenicline is 
a more effective aid to smoke cessation than the others 
(Kotz, Brown, West, 2014; Walker et al., 2017). Despite 
its proven effectiveness, some patients do not still respond 
to Varenicline. At this point, individual differences in 
response to Varenicline can be caused by genetic factors 
(Santos et al., 2015; Tomaz et al., 2015).
Multi-drug resistant-1 (MDR-1) is a gene located 
on chromosome 7q21 and encodes a transporter protein 
called P-glycoprotein (P-gp), which is the member of 
a family of proteins in which only one subgroup has 
a role in multidrug resistance (MDR) (Miller, Bauer, 
Hartz, 2008). P-gp is responsible for the cellular efflux 
of a variety of drugs and cellular metabolites across the 
plasma membrane and reduces exposure to potentially 
toxic compounds of intracellular environment (Yamada 
et al., 2011). It is also suggested that this transporter 
functions as a protective barrier to keep toxins out of the 
body by excreting these compounds into bile (Wang et al., 
2004), urine and intestinal lumen (Marzolini et al., 2004). 
In addition, P-gp is released in the epithelium of brain 
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choroid plexus, as well as the luminal surface of blood 
capillaries of brain (Cordon-Cardo et al., 1989). 
The MDR1 gene is a highly polymorphic gene with 
more than 50 single-nucleotide polymorphisms (SNPs) 
(Breier et al., 2005). C3435T SNP is one of the most 
popular MDR1 polymorphisms and effects the expression 
and functions of P-gp (Hoffmeyer et al., 2000).
For that reason, we assume that P-gp could be a 
factor that may affect the level of substance that can cause 
addiction once it penetrates into the brain.
Therefore, we aimed to determine the genotype and 
allele frequencies of MDR C3435T polymorphisms and 
to identify their relationship with Varenicline efficacy in 
smokers.
MATERIAL AND METHODS
Subjects
The study was performed between July 2015 and 
May 2016 at a smoking cessation clinic of Pamukkale 
University Medical Faculty, in Denizli, Turkey. When 
α=0.05 and β=0.2 are accepted and the lowest person to 
be taken to work was found as 152. Totally 158 cigarette 
smokers (male:138, female:20) were included in the study. 
Also 52 non-smoker healthy volunteers were included to 
the study as control group. Exclusion criteria for control 
and smoker groups are any chronicle disease. 
A questionnaire included gender, age, Fagerström 
Test for Nicotine Dependence (FTND) (Heatherton et 
al., 1991), previous attempts to quit, former and current 
diseases and medications etc. was performed on smokers. 
In addition, face to face interviews with smokers were 
performed for smoking cessation. All smokers were 
prescribed Varenicline up to 0.5 mg a daily for 3 days, 
then 0.5 mg twice a day for 4 days, then 1.0 mg twice a 
day for 11 weeks. The smoking cessation was planned 
to be 7-14 days after Varenicline initiation (Jorenby et 
al., 2006). After the first visit on the day 1st, follow-up 
visits were scheduled on days 15th, 29th, 57th, and 85th. 
The self-reported smoking status and exhaled carbon 
monoxide concentrations were assessed on each visit. 
Then, smoking cessation success was evaluated in the 6th 
month. Firstly, the genotype distributions of “smokers” 
and “non-smokers” were compared. Secondly, the 
genotype distributions of “quitters” and “non-quitters” 
were compared. 
The study protocol conformed to the ethical 
guidelines of the Declaration of Helsinki as reflected in 
the previous approval released by the institution’s human 
research committee. All volunteers were acknowledged 
about the study and written consent was taken. The study 
was approved by the Ethics Committee of Pamukkale 
University (PAU 02.09.2013/31488).
Blood sample
Blood samples from all subjects were collected into 
2 ml tubes containing ethylene diamine tetra acetic acid.
Genetic analysis
Deoxyribonucleic acid (DNA) samples were isolated 
from peripheral blood leukocytes by standard phenol/
chloroform extraction method (Ponez et al., 1982). MDR1 
C3435T polymorphism of genotyped by polymerase 
chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) method. PCR was performed with thermal 
cycler (Techgene, NJ, USA) and a PCR assay using the 
forward primer 5’-TGC TGG TCC TGA AGT TGA TCT 
GTG AAC-3’ and the reverse primer 5’ -ACA TTA GGC 
AGT GAC TCG ATG AAG GCA-3’ 3’ was performed 
with 10× buffer, 1.5 mM MgCl2 and 0.2 mM each dNTP, 
100 ng genomic DNA and 1 U Taq DNA polymerase 
(Ameyaw et al., 2001). The PCR protocol was as follows: 
initial 2 min at 94 0C followed by 35 cycles, consisting of 
denaturation for 30 s at 94 0C, annealing for 30 s at 60 0C, 
and extension for 30 s at 72 0C (Schwab et al., 2003). The 
PCR product (248 bp in size) was digested at 37 0C for 4 
h with MboI restriction enzyme (Fermentes, Germany), 
resulting in the following fragments: 172, 60 bp in wild 
type homozygotes (C/C genotype), 238 bp to T/T genotype 
and 238 pb, 170 bp and 60 bp to the C/T genotype. These 
fragments were separated with gel electrophoresis on 3% 
agarose gel stained with ethidium bromide, and observed 
under ultraviolet light.
Statistical analysis
SPSS 15.0 for Windows Computing Program 
was used for statistical analysis of the data. Statistical 
significance of the observed genotype frequencies was 
evaluated according to Hardy-Weinberg rule compared 
to the expected genotype frequencies. Hardy-Weinberg 
equilibrium was evaluated by the x2 test. 
The difference in allele and genotype frequencies 
between the smokers and the ones in the control group 
was determined by using the chi-square test. The chi-
square test was also used to compare difference between 
the smoking cessation rates according to genotype 
distribution. The ANOVA test was also used to compare 
the difference between FTND scores.
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Logistic regression analysis was used to determine 
the factors affecting smoking cessation.
RESULTS
There were 158 cigarette smokers and 52 never 
smokers (control group) in the current study. Cigarette 
smokers and control groups were compared. The mean 
age was similar in smokers and control group (respectively 
36.7±9.5 and 35.9±11.0), (p=0.6). Some characteristics of 
smokers were shown on Table I. The majority of smokers 
were male, married and high school graduates. The 
education and marital status were also similar in smokers 
and control group. Gender distribution between the groups 
was also evaluated. Percentage of men was significantly 
higher in smokers (87.3%) than the control group (32.7%), 
(p=0.01). 
In current study, the MDR-1 C3435T gene 
distribution was investigated in terms of possible effects 
on smoking habit and smoking cessation. The frequency 
of the genotype MDR-1 C3435T gene in smokers and 
the control groups did not show a significant deviation 
from the Hardy-Weinberg equilibrium. Observed and 
expected frequencies for the gene were in Hardy-Weinberg 
equilibrium in both the smokers and the control groups, 
respectively, (χ2 =3.6 p>0.05), (χ 2 = 3.78 , p>0.05).
In the study population; MDR gene distribution 
based on gender was given on Table II. There was no 
statistically difference (p=0.08).
Varenicline treatment to quit smoking was given to 
all smokers. In our study, smoking cessation success was 
evaluated in the 6th month and it was 57%. This rate was 
evaluated based on gender, but no difference was found, 
(p=0.85), (Table III). It was 55.0% in females, and 57.2% 
in males.
The genotype distributions of the groups were 
compared on the Table IV. There was no significant 
difference between control and smoker groups in terms of 
genotype distribution (p=0.56). In addition, C and T allele 
presences were evaluated in these groups. Percentages of 
C and T allele presence were not significantly different 
(respectively p=0.29, p=0.88), (Table IV). 
The MDR-1 C3435T genotype distributions of these 
two groups (“smoking quitters” and “non-quitters”) were 
TABLE I -  Some socio-demographic features of the smokers and non-smokers
Smokers Non-smokers p*
n % n %
Gender 
       Male 
       Female 
Marital status 
       Not Married 
       Married 
Educational status 
       Primary school 
       High school  
       University 
 
138 
20 
 
26 
132 
 
53 
73 
32
 
87.3 
12.7 
 
16.5 
83.5 
 
33.6 
46.2 
20.3
 
17 
35 
 
8 
44 
 
14 
26 
12
 
32.7 
67.3 
 
15.4 
84.6 
 
26.9 
50.0 
23.1
 
 
P=0.01 
 
 
P=0.91 
 
 
P=0.70
Total 158 100.0 52 100.0
*chi-square test results
TABLE II - The MDR-1 C3435T gene distribution according to gender in each person
Gender
Total
p*Male Female
n % n % n %
Genotyppes
CC 31 20.0 4 7.3 35 16.7
CT 86 55.5 37 67.3 123 58.6 0.08
TT 38 24.5 14 25.5 52 24.8
Total 155 100.0  55 100.0 210 100.0
*chi-square test result
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compared and there was no significant difference in terms 
of genotype distribution (p=0.27), (Table IV). In addition, 
C and T allele presences were compared between these 
two groups, and no significant difference was observed 
(p=0.11), (p=0.73), (Table IV). 
A comparison on the genotype distributions of the 
three groups (quitters, non-quitters and control) were 
also done in Table IV. Genotype and alleles distributions 
of three groups were not different, (p=0.43), (Table 
IV). But one point is remarkable when three groups are 
compared: The C allele positivity was found 80.8% in the 
control group and 77.8% in quitters, while it decreases 
to 67.6% in non-quitters (Table IV). But this difference 
was not statistically significant (p=0.19). When viewed 
in reverse order; the TT genotype positivity was found 
as 19% in control group and 22% in smoking quitters’ 
group, while it increased to 32% in non-quitters 
(Table IV). 
Smoking cessation rate was 57.0% in the 6th month. 
The quit rates according to genotype distribution were 
given in Figure I. In the presence of C allele, the quit 
rate was found 60.3%, but it was 57.6% in the presence 
of T allele. The lowest quit-rate was observed in the TT 
genotype (47.6%). But there was no statistically significant 
correlation between MDR 1 C3435T subgroups and 
smoking cessation rate. 
The FTND score was used to determine the level of 
nicotine addiction. The correlation between FTND score 
and gene distribution, which may be related to the smoking 
cessation, was examined. FTND score was 5.65 ± 2.48 in 
those with CC genotype and 5.76 ± 2.14 in those with CT 
gene and 5.74 ± 2.28 in those with TT genotype. There 
was a mild increase in the presence of T allele This is not 
statistically significant (p=0.97).
Logistic regression analysis was done by modeling 
with possible variables (age, gender, education status, 
genotype status, FTND score) (Table V). The values 
in the two variables were determined at the limit of 
significance. These are FTND score and education 
status. According to multiple analysis results; Not being 
able to quit smoking was 3 times higher in high nicotine 
dependence persons than mild dependence (p=0.06). 
Also it was 4.6 times more than high school graduates, 
compared to those who graduated from primary school 
(p=0.06). According to genotype status, no difference 
was detected. The presence of C allele is slightly 
protective. In other words, in the person having the 
TT genotype, the probability of non-quitting increases 
TABLE III - The success of smoking cessation according to gender
Smoking quitters Non-quitters p*
n % n %
Male 79 57.2 59 42.8 0.85
Female 11 55.0 9 45.0
Total 90 57.0 68 43.0
*chi-square test result
TABLE IV - Comparisons of The MDR-1 C3435T genotypes and alleles distribution in all groups 
Control 
(n=52)
Smokers 
(n=158)
p* Quitters (n=90) Non-quitters 
(n=68)
p* p*#
n % n % n % n %
Genotypes 
    CC
 
9 17.3
 
26 16.5
 
14 15.6
 
12 17.6
    CT 33 63.5 90 57.0 0.56 56 62.2 34 50.0 0.27 0.43
    TT 10 19.2 42 26.6 20 22.2 22 32.4
Alleles        
C presence** 
               TT  
T presence*** 
              CC 
 
42
10
43
9
80.8
19.2
82.7
17.3
116
42
132
26
73.4
26.6
83.5
16.5
0.29
0.88
70
20
76
14
77.8
22.2
84.4
15.6
46
22
56
12
67.6
32.4
82.4
17.6
0.11 
 
0.73
0.19 
 
0.93
*chi-square test results; **CC+ and CT +; ***CT+ and TT+; # quitters, non-quitters and control groups were compared
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1.3 times. However, this is not statistically significant 
(p=0.22). 
DISCUSSION
Smoking remains the leading preventable cause 
of illness (Centers for Disease Control and Prevention, 
2005). Research over the past three decades has identified 
effective treatments for smoking, including counseling, 
social support, and several pharmacotherapies (Fiore et 
al., 2008). However, current smoking cessation treatments 
have limited the efficacy (Thorndike et al., 1998; Solberg 
et al., 2001). 
In our study; 87% of the smokers was male 
(p=0.001). According to the World Health Organization 
(2015), the smoking rate of men was five times higher 
than female; 36% vs. 7% respectively. Our findings are 
consistent with this report.
In current study, cessation rate was found as 57% in 
the 6th month. This rate was 55.0% in female, and 57.2% 
in male. In various studies using Varenicline, success rates 
between 30% and 65% have been reported (Jorenby et al., 
2006; Fagerström et al., 2010; Saglam, 2012).
Recent studies have indicated that some genes may 
affect Varenicline treatment during smoking cessation 
trials (Santos et al., 2015; King et al., 2012; Swan et al., 
2012). King et al. (2012) provided the evidence referring 
that multiple genetic loci contributes to smoking cessation 
and therapeutic response. Santos et al. (2015) investigated 
CHRNA4 rs1044396 gene in smoking cessation study and 
reported that patients treated with Varenicline including 
TT or CT genotypes had an OR of 2.18 for smoking 
cessation success compared with patients with CC 
genotype. In addition to them, there are only two studies 
concerning the literature investigating the relationship 
between Varenicline and P-gp. According to Rollema 
(2010), Varenicline is neither a substrate nor an inhibitor 
of P-gp. Similar results were also reported in the other 
study (Faessel et al., 2008).
In current study, the MDR 1 C3435T gene 
distribution was investigated for possible effects on 
smoking cessation. Because P-gp is expressed as 
intestinal and blood-brain barrier and it reduces the 
exposure to potentially toxic compounds of intracellular 
environment (Yamada et al., 2011). We also assume 
that P-gp may be a factor that may affect the level of 
TABLE V - Effective Factors on Smoking Cessation Success According to Regression Analysis 
df Sig. Exp(B)
95% C.I.for EXP(B)
Lower Upper
Gender (female) 1 .809 .88 .319 2.439
Age 1 .770 .99 .956 1.034
FTND score (mild) 2 .059
middle 1 .364 1.44 .657 3.149
high 1 .018 3.08 1.211 7.833
Education status (primary) 3 .061
Secondary school 1 .187 1.99 .717 5.509
High school 1 .008 4.64 1.506 14.314
University 1 .271 1.77 .641 4.882
MDR (cc) 2 .227
CT + 1 .381 .66 .262 1.670
TT + 1 .618 1.30 .462 3.665
Constant 1 .388 .42
FIGURE 1 - Cessation rates by genotype distributions
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substance causing addiction once it penetrates into the 
brain.
On reviewing the literature; we did not find any 
studies on the MDR1 C3435T gene distribution and 
smoking. However, the genotype distribution of smokers 
was reported as similar to the genotype distribution of 
the normal population in Denizli (Turgut, Turgut, Atalay, 
2006).
When we look at our findings; genotype and alleles 
distributions of three groups (smoking quitters, non-
quitters and control groups) did not different (p=0.43). 
Similar smoking cessation rates were also obtained 
in each genotype groups (47.6% in TT genotype, 53.8% 
in CC genotype, 62.2% in CT genotype), (p=0.27). In 
addition, similar FTND scores were obtained in each 
group (p=0.97). 
When the factors affecting the cessation rates are 
analyzed by multivariate analysis; as expected, the rates 
of non-quitters were high in high nicotine addicts. Also the 
rates of non-quitters were high in high school graduates. 
In addition; MDR1 C3435T gene distribution didn’t have 
an effect on smoking cessation.
These findings indicate that the MDR1 C3435T 
gene distribution does not significantly affect the success 
of the Varenicline treatment. This data is compatible with 
the study carried by Rollema et al. (2010).
But nevertheless, there are some notable points in 
the current study even if it is not statistically significant. 
1. The percentage of TT genotype in non-quitters 
(32%) is slightly higher than quitters (22%).
2. The FTND score indicating nicotine dependence 
was found to be slightly higher in the TT genotype carriers. 
And there was a positive correlation between the FTND 
score and the T allele carrier.
These findings have shown that individuals with TT 
genotypes may be more addicted to nicotine. Individuals 
with TT genotypes have lower levels of P-gp, and these 
individuals may be exposed to more toxic substances 
(Schwab et al., 2003). Because P-gp is expressed intestinal 
and blood-brain barrier and reduces exposure to potentially 
toxic compounds of intracellular environment (Yamada et 
al., 2011). We think that some of the substances in the P-gp 
deficiency may go into the brain and create addiction. 
Consequently “non-quitters rate” increased 1.3 times in 
the presence of TT genotype.
The frequency of P-gp polymorphism in smokers 
has not been yet studied. In this context, our results are 
first and suggest that the smoking cessation success in 
Varenicline treatment is generally not affected by P-gp 
polymorphism. However, the TT genotype may be a small 
risk factor for nicotine dependence. 
There are some limitations in our study. First, our 
sample size of patients treated with Varenicline is relatively 
small and, consequently, our statistical power is relatively 
low. However, we were able to identify differences among 
genotypes, even including some potential confounders. 
But we were not able to add other biological aspects or 
environmental factors which could be important, such as 
functionality of the receptors, depression and motivation.
CONCLUSIONS
The smoking cessation success in Varenicline 
treatment is generally not affected by the MDR 1 C3435T 
gene polymorphism. However, the TT genotype seems 
related to be nicotine dependence. 
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